Mixed-phenotype acute leukemia: Current challenges in diagnosis and therapy

Ofir Wolach*, Richard M. Stone

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of review Mixed-phenotype acute leukemia (MPAL) is a rare disease that poses many diagnostic and therapeutic challenges. Patients with MPAL are considered to have poor outcomes. The difficulties in classifying this leukemia, the lack of prospectively collected data concerning therapeutic outcomes, and rare incidence result in much uncertainty as to the best approach for patients with MPAL. Recent findings Recent studies demonstrated that most MPALs are associated with cytogenetic abnormalities; genetic sequencing studies disclose a high frequency of somatic mutations in genes encoding epigenetic regulators, tumor suppressors, and transcription factors. The limited available data suggest that higher remission rates are achieved with acute lymphoblastic leukemia-like induction regimens compared with acute myeloid leukemia-type approaches. Allogeneic transplantation in first remission may be associated with improved survival compared with consolidation chemotherapy. Summary Advances in understanding the genetic landscape of MPAL may allow a more biologically driven classification of this heterogeneous group of leukemias in the future that will lead to optimized therapies for individual patients. Most data that inform therapy are based on retrospective, uncontrolled studies; prospective trials that incorporate targeted approaches based on genetics and immunophenotype are needed.

Original languageEnglish
Pages (from-to)139-145
Number of pages7
JournalCurrent Opinion in Hematology
Volume24
Issue number2
DOIs
StatePublished - 1 Mar 2017
Externally publishedYes

Keywords

  • acute lymphoblastic leukemia-like therapy
  • allogeneic transplantation
  • genetics
  • mixed-phenotype acute leukemia

Fingerprint

Dive into the research topics of 'Mixed-phenotype acute leukemia: Current challenges in diagnosis and therapy'. Together they form a unique fingerprint.

Cite this